Analysts expect Mira Pharmaceuticals, Inc. to report revenue of 0.00 for Q4 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 25, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.09 M | 10.25 M | 10.46 M | |||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.56 M | 8.82 M | 9.49 M | |||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.83 M | 9.53 M | 9.98 M |
Analysts expect Mira Pharmaceuticals, Inc. to report earnings per share of -1.23 for Q3 25, against a range of -1.30 to -1.16. The most recent reported quarter, Q2 25, came in at -0.09 , in line with the -0.09 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.14 | -0.17 | -0.11 | -0.09 | - | - | - | - | - | - | - | - | ||
| High Estimate | -0.15 | -0.16 | -0.11 | -0.09 | -1.16 | -0.04 | 0.34 | 0.43 | -0.86 | 0.09 | 0.16 | 0.18 | ||
| Low Estimate | -0.17 | -0.18 | -0.13 | -0.09 | -1.30 | -0.04 | 0.30 | 0.37 | -0.94 | 0.07 | 0.14 | 0.16 | ||
| Consensus Estimate | -0.16 | -0.17 | -0.12 | -0.09 | -1.23 | -0.04 | 0.32 | 0.40 | -0.90 | 0.08 | 0.15 | 0.17 |